HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic.

Abstract
Patients with primary antibody deficiency (PAD) are prone to mycoplasma infection with unusual strains which may be resistant to conventional antibiotics. Mycoplasmas were isolated from the joint fluid (Ureaplasma urealyticum) of two PAD patients with arthritis and from the cerebral spinal fluid (Mycoplasma maculosum) in one with meningitis, the latter probably originating from the patient's dog. Combinations of doxycycline and quinolones or macrolides failed to clear the infections, but after demonstrating in-vitro sensitivity to the pleuromutilin, Econor, for two of the isolates, all three patients responded to oral treatment with Econor. The infection was completely eradicated in two patients, with the emergence of a resistant strain in the third. Mycoplasma infection should be considered in PAD patients with unexplained sepsis. Pleuromutilins such as Econor are powerful new anti-mycoplasmal agents which provide an additional therapeutic option when patients fail to respond to conventional antibiotics.
AuthorsC Heilmann, L Jensen, J S Jensen, K Lundstrom, D Windsor, H Windsor, D Webster
JournalThe Journal of infection (J Infect) Vol. 43 Issue 4 Pg. 234-8 (Nov 2001) ISSN: 0163-4453 [Print] England
PMID11869060 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright 2001 The British Infection Society.
Chemical References
  • Anti-Bacterial Agents
  • Diterpenes
  • Polycyclic Compounds
  • pleuromutilin
Topics
  • Adolescent
  • Adult
  • Anti-Bacterial Agents (therapeutic use)
  • Common Variable Immunodeficiency (complications)
  • Diterpenes (therapeutic use)
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Humans
  • Immunocompromised Host
  • Male
  • Mycoplasma (drug effects, isolation & purification)
  • Mycoplasma Infections (drug therapy, immunology)
  • Polycyclic Compounds
  • Treatment Outcome
  • Ureaplasma Infections (drug therapy, immunology)
  • Ureaplasma urealyticum (drug effects, isolation & purification)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: